



10th North of England Breast Cancer Symposium

www.neonc.org.uk

Dr Ged Avery

Consultant Radiologist appointed to Hull and East Yorkshire NHS Trust in 1992. Clinical lead for PET CT and nuclear medicine. Honorary reader at University of Hull.

Dr Elena Provenzano



Dr Elena Provenzano is Lead Breast Histopathologist for the Cambridge Breast Unit at Addenbrooke's Hospital. Her current role combines clinical work and research, with key interests in the molecular taxonomy of breast cancer and assessment of tumour response to neoadjuvant therapy. She is a co-investigator in several breast cancer trials that include ARTemis, PARTNER, PRIMETIME and Neo-RT clinical trials at Addenbrooke's Hospital. She recently participated as a member of the BIG/ NABCG Residual Disease Working Group composing guidelines for assessment of breast cancer post neoadjuvant chemotherapy, and has recently become a member of the CM-Path Clinical Trials team.

Mr Amit Goyal



Amit Goyal is a Consultant Oncoplastic Breast Surgeon & Associate Professor at the Royal Derby Hospital, UK.

His research as a part of the ALMANAC trial and NEW START, has helped to understand and refine the sentinel node biopsy technique. He is the Chief Investigator of the UK-ANZ POSNOC trial and the ATNEC trial. He is the Oncology and Breast Specialty Editor of the Surgery journal (UK). He is the breast research lead and Association of Breast Surgery representative for East Midlands.

His surgical practice is focussed mainly on oncoplastic & reconstruction surgery and cosmetic breast surgery and regularly hosts international fellows for oncoplastic & cosmetic breast surgery training.

Dr Carolyn Taylor



Carolyn Taylor is a consultant clinical oncologist and clinical research fellow. She studied medicine at Oxford University. Her clinical training was in general medicine and then clinical oncology. She gained Fellowship of the Royal College of Radiologists in 2004.

Since then she has worked as a clinical research fellow at the Clinical Trial Service Unit, doing research alongside clinical work. She completed her DPhil on the risk of heart disease after breast cancer radiotherapy in 2008. She works in the Early Breast Cancer Trialists' Collaborative Group on trials of surgery and radiotherapy and in a Cancer Research UK research program on the benefits and risks of breast cancer treatments.



10th North of England Breast Cancer Symposium

www.neonc.org.uk

Dr Rob Stein



Rob Stein was appointed Consultant in Medical Oncology at University College London Hospitals since 1997 and is Professor of Breast Oncology at UCL.

After completing an undergraduate degree and PhD in Physiology at the University of Cambridge, he went on to study medicine there. His oncology training was at St George's Hospital Medical School and at UCLH. Between 1994 and 2002 he was a clinician scientist at the UCL branch of the Ludwig Institute for Cancer Research, working on the development of PI3-kinase inhibitors and on the proteomics of cell signalling.

Professor Stein's research interests are in the treatment of luminal breast cancer and in the validation of prognostic and predictive biomarkers. He was involved in the early clinical development of aromatase inhibitors, and more recently, in the design and management of several large-scale breast cancer clinical trials with a translational component. He is Chief Investigator of the OPTIMA study of the use of tumour gene-expression biomarker assays to direct chemotherapy decisions for primary breast cancer. He has been a member of the Breast Cancer Now SAB and has acted as an advisor for several NICE appraisals. He is a member of the NCRI Breast Clinical Studies Translational & Imaging sub-group and of the executive committee of the UK Breast Cancer Group.

Prof Michele De Laurentiis, MD, PhD



*Director, Breast Oncology, Department of Senology,
National Cancer Institute "Fondazione Pascale" – Naples - ITALY*

Michele De Laurentiis took his Medical Degree in 1989 at the University 'Federico II' in Naples, Italy and he was awarded a clinical fellowship in medical oncology at the same University. Between 1992 and 1994 he worked as research fellow at the Division of Medical Oncology, The University of Texas Health Science Center, San Antonio, TX, USA, focusing on the development of prognostic models for breast cancer. In 2000 he obtained a PhD degree for clinical research in oncology and was also appointed as attending physician at the division of medical oncology of the 'Federico II' University Hospital. Between 2002 and 2010 he held the position of Assistant Professor of Medical Oncology in the Department of Endocrinology and Molecular and Clinical Oncology, University 'Federico II' – Naples - ITALY, where he took responsibility for breast cancer systemic therapy and clinical and translational breast cancer research. In 2010 he moved to the National Cancer Institute 'Fondazione Pascale', where he took the Direction of Breast Oncology. In 2015 he was appointed as Affiliate Professor at the Temple University of Philadelphia, PA, USA. He currently heads the division of Breast Oncology and is the Coordinator of the Comprehensive Cancer Center at the National Cancer Institute "Fondazione Pascale" at Naples, Italy.

Michele De Laurentiis is a member of the American Association of Clinical Oncology (ASCO), of the European Society of Medical Oncology (ESMO) and of the Italian Society of Medical Oncology (AIOM). He is a founding member of the main Italian group for clinical research in breast cancer (Gruppo Italiano Mammella; GIM) He also sits as a member in the Scientific Committee and the Translational Research Committee of the GIM and he is directly responsible for the coordination of clinical breast cancer trials and translational studies. Prof. De Laurentiis holds steering committee positions in several international trials and in some of these he acts as principal investigator.

Prof. De Laurentiis serves as reviewer for various journals and he has authored about 140 papers on peer-reviewed journals. His main research interests are breast cancer treatment and prognostic and predictive factors.



10th North of England Breast Cancer Symposium

www.neonc.org.uk

Dr Toral Gathani



Toral was appointed as a Consultant Oncoplastic Breast Surgeon at the Oxford University Hospitals NHS Trust and Clinical Epidemiologist at the Cancer Epidemiology Unit in 2013.

Toral studied Medicine at the University of St Andrews and Guy's and St Thomas' Medical School graduating in 1999 with Honours. She passed the Fellowship of the Royal College of Surgeons in 2010. She subsequently subspecialised in Oncoplastic and Reconstructive Breast Surgery and was awarded a National Oncoplastic Breast Surgery Fellowship at the Nottingham Breast Institute in 2011.

Toral spent time in the Cancer Epidemiology Unit in 2003-2006 when she completed the research for her MD thesis under the supervision of Dame Professor Valerie Beral. She continued to develop her interest in epidemiology during her specialist surgical training and has spent a year working in India establishing multicentre studies related to breast cancer.

Her main research interests are in the epidemiology of breast cancer in South Asians and the South Asian diaspora.

Prof Rob Coleman



Professor Robert (Rob) Coleman is Emeritus Professor of Medical Oncology at Weston Park Hospital and the University of Sheffield. He graduated in medicine from Kings College Hospital Medical School in 1978 and trained in London and Edinburgh before moving to Sheffield in 1991 where he was instrumental in developing clinical cancer research in the city and establishing an internationally respected bone oncology research team in Sheffield. Rob has held many leadership roles within the university and the National Institute for Health Research (NIHR) Cancer Research Network.

Recently retired from the university, Professor Coleman remains research active and has written more than 400 scientific articles and book chapters and still leads a number of national and international clinical trials. He is a past-president of the Cancer and Bone Society, the founding editor of "Journal of Bone Oncology" and a trustee for Breast Cancer Now, the largest breast cancer research charity in the UK. He is also a Trustee at St Luke's Hospice in Sheffield and for Weston Park Cancer Charity.

Since 2014 he has been a part-time Medical Director for the global independent medical education provider, prIME Oncology™ developing and delivering both live and on-line educational programmes for oncologists and other providers of cancer care.

Dr Mark Verrill



Dr Verrill completed his studies in Medicine at the University of Cambridge and University College London, qualifying in 1989. He was awarded Membership of the Royal College of Physicians in 1993 and Fellowship in 2003. He undertook his Oncology Training at the Royal Marsden Hospital and Institute of Cancer Research, London.

Dr Verrill was appointed Cancer Research UK Senior Lecturer in Medical Oncology at Newcastle University and Honorary Consultant Medical Oncologist in the Newcastle Hospitals Trust in 1999. He moved in to his current NHS post in 2007. He is currently Head of the Department of Medical Oncology in the Northern Centre for Cancer Care and about to start a second stint lead clinician for breast cancer in the North of England Cancer Alliance. Dr Verrill's primary research interest is clinical trials of systemic therapies for breast cancer.



Prof David Dodwell



He is a Consultant in Clinical Oncology at St James Institute, Leeds and visiting professor at Sheffield Hallam University. He leads the breast oncology group of the YCN and have co-ordinated the implementation of guidelines for the use of aromatase inhibitors, herceptin, bisphosphonates and taxanes as adjuvant therapy.

As a member of the Faculty of Clinical Oncology, Royal College of Radiologists, he has responsibility for co-ordinating the functions and determining the policy of the RCR in relation to oncology including training, examinations, professional standards, audit, research, accreditation and response to national initiatives. He is co-chair of a group charged with the revision of advice to oncologists acting as expert witnesses and chairs the Site Orientated Electronic Network for breast oncology within the RCR. He also represents the Joint Council for Clinical Oncology (JCCO). This group allows liaison and co-operation between Clinical and Medical Oncology the two specialties involved in solid tumour oncology service configuration and standards of care within the UK.

He has been involved in the development and implementation of a nationally agreed national data set to capture and analyze the use of systemic therapy in solid cancer and haematology. He has been the of the Breast Tri-network group which comprises 35 breast oncologists across the Yorkshire, North Trent and East Riding Cancer Networks. The group assess new interventions, determine regional policy and co-ordinate and prioritize applications to the Interim Cancer Drug Fund. He is actively involved in research and has extensive list of publications in national and international journals.

Dr Richard Berman



Dr Berman graduated in medicine at Charing Cross and Westminster Medical School (University of London) in 1996. He initially trained as a GP and became a member of the Royal College of General Practitioners (MRCGP) in 2001. However, as a GP he developed a real interest in palliative and supportive care, so left general practice and enrolled on a specialist training programme for palliative medicine in 2002 (at the North West Deanery in Manchester, which oversees postgraduate medical education).

He now works as Consultant in Palliative Medicine and Honorary Senior Lecturer at The Christie. His role involves management of pain and symptom control in cancer patients, to help them through treatment, as well as caring for patients with advanced disease and those towards the end of life.

Dr Berman is also NHS England's National Clinical Lead for Enhanced Supportive Care.